Healthcare royalties company Royalty Pharma (NASDAQ: RPRX) will be announcing earnings results this Wednesday before the bell. Here’s what to look for.

Royalty Pharma met analysts’ revenue expectations last quarter, reporting revenues of $568.2 million, flat year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts’ EPS estimates.

Is Royalty Pharma a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Royalty Pharma’s revenue to grow 9.8% year on year to $590 million, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $1.02 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Royalty Pharma has missed Wall Street’s revenue estimates six times over the last two years.

Looking at Royalty Pharma’s peers in the branded pharmaceuticals segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bristol-Myers Squibb posted flat year-on-year revenue, beating analysts’ expectations by 7.8%, and Merck reported a revenue decline of 1.9%, falling short of estimates by 1.1%. Bristol-Myers Squibb traded down 3.9% following the results while Merck was also down 2.7%.

Read our full analysis of Bristol-Myers Squibb’s results here and Merck’s results here.

The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the branded pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Royalty Pharma is up 6.4% during the same time and is heading into earnings with an average analyst price target of $42.15 (compared to the current share price of $37.85).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.